"SILVAMP TB LAM" Rapid Urine Tuberculosis Test Predicts Mortality in Patients Hospitalized With Human Immunodeficiency Virus in South Africa

Clin Infect Dis. 2020 Nov 5;71(8):1973-1976. doi: 10.1093/cid/ciaa024.

Abstract

Reducing diagnostic delay is key toward decreasing tuberculosis-associated deaths in people living with human immunodeficiency virus. In tuberculosis patients with retrospective urine testing, the point-of-care Fujifilm SILVAMP TB LAM (FujiLAM) could have rapidly diagnosed tuberculosis in up to 89% who died. In FujiLAM negative patients, the probability of 12-week survival was 86-97%.

Keywords: HIV; Tuberculosis; lipoarabinomannan; mortality; point-of-care.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Delayed Diagnosis
  • HIV
  • HIV Infections* / complications
  • Humans
  • Lipopolysaccharides
  • Retrospective Studies
  • Sensitivity and Specificity
  • South Africa / epidemiology
  • Tuberculosis* / diagnosis

Substances

  • Lipopolysaccharides
  • lipoarabinomannan